{"id":"ga-depot","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Decreased libido"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1200994","moleculeType":"Small molecule","molecularWeight":"256.03"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GA Depot works by providing sustained release of a GnRH agonist, which initially stimulates the pituitary gland but with continuous exposure leads to downregulation of GnRH receptors and suppression of gonadotropin secretion. This results in reduced testosterone or estrogen levels depending on the indication, making it useful for hormone-dependent conditions.","oneSentence":"GA Depot is a long-acting gonadotropin-releasing hormone (GnRH) agonist depot formulation that suppresses luteinizing hormone and follicle-stimulating hormone secretion.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:35.475Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Hormone-responsive breast cancer"},{"name":"Endometriosis"}]},"trialDetails":[{"nctId":"NCT03362294","phase":"PHASE2","title":"Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mapi Pharma Ltd.","startDate":"2017-12-11","conditions":"Primary Progressive Multiple Sclerosis","enrollment":30},{"nctId":"NCT02212886","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS","status":"COMPLETED","sponsor":"Mapi Pharma Ltd.","startDate":"2014-10","conditions":"Multiple Sclerosis","enrollment":25},{"nctId":"NCT04121221","phase":"PHASE3","title":"A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS","status":"COMPLETED","sponsor":"Mapi Pharma Ltd.","startDate":"2019-09-19","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1016}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GA Depot","genericName":"GA Depot","companyName":"Mapi Pharma Ltd.","companyId":"mapi-pharma-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GA Depot is a long-acting gonadotropin-releasing hormone (GnRH) agonist depot formulation that suppresses luteinizing hormone and follicle-stimulating hormone secretion. Used for Advanced prostate cancer, Hormone-responsive breast cancer, Endometriosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}